Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
MENLO PARK, Calif., March 08, 2018 -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present an overview of the company at the Cowen & Company 38th Annual Healthcare Conference.
- Location: Boston, MA
- Presentation date: Wednesday, March 14, 2018
- Presentation time: 10:40 a.m. ET
A live audio webcast and archive of the presentation will be available at http://investor.dermira.com.
About Dermira
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s pipeline includes two late-stage product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate (formerly DRM04), for which a New Drug Application is under review by the U.S. Food and Drug Administration for the treatment of primary axillary hyperhidrosis (excessive underarm sweating beyond what is needed for normal body temperature regulation), and lebrikizumab, in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. Dermira is headquartered in Menlo Park, Calif. For more information, please visit http://www.dermira.com. Follow @DermiraInc on Twitter and LinkedIn.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com), LinkedIn page (https://www.linkedin.com/company/dermira-inc) and corporate Twitter account (@DermiraInc) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website, LinkedIn page and Twitter account in addition to following its SEC filings, press releases, public conference calls and webcasts.
Contacts:
Media:
Erica Jefferson
Vice President, Corporate Communications
650-421-7216
[email protected]
Investors:
Ian Clements, Ph.D.
Vice President, Investor Relations
650-422-7753
[email protected]
Robert H. Uhl
Westwicke Partners
Managing Director
858-356-5932
[email protected]
